Back to catalog

Product details

Thymosin Alpha-1

$27.99$39.9910mg · per unit

Save $12.00 per unit with current offers

Explore Thymosin Alpha-1 amounts, pricing, and product information.

Front view of Thymosin Alpha-1
Thymosin Alpha-110mgRESEARCH USE ONLY
-30%

Select your product

Amount
Bundle and save

Bundle savings apply after the sale price. Same product and amount: 2–3 bottles save 3% extra, 4–10 save 6%, and 11+ save 30%.

10mg · 1 unit · Total

$27.99$39.99

$27.99 per unit

Save $12.00 total

WINTER30 −30%

Save your selection in the cart. Ordering is not open. Contact us for availability.

For laboratory research only. Not for human or veterinary use. Research-use policy.

Know your compound

Compound information

Thymosin Alpha-1

Thymosin alpha 1 is indexed under Thymalfasin in PubChem.

Identity references 1 source
Catalog identity
Thymosin Alpha-1
Intended use
Laboratory research
Research names
Thymosin alpha 1 · Thymosin α1 · Tα1
Reference molecule
Thymalfasin
PubChem record
CID 16130571
Molecular formula
C129H215N33O55
Molecular weight
3108.3 g/mol

Molecular data describe the reference compound in PubChem, not a laboratory analysis of this product or batch.

Primary literature

Verified research references

Primary-source bibliography for the named compound. These studies did not test this catalog item.

Randomized human research included

Thymosin Alpha-12 verified references

Identity note

The cited papers use Thymosin alpha 1, thymosin α1, and Tα1; these source spelling and typography variants do not establish catalog-item equivalence.

  1. Immune enhancement in patients with predicted severe acute necrotising pancreatitis: a multicentre double-blind randomised controlled trial.

    Ke L · 2022 · Intensive Care Med

    Study design
    Randomized controlled trial
    Research context
    Human research
    Sample size
    508 participants or samples
    Study population
    Patients with predicted severe acute necrotising pancreatitis

    PMID: 35713670

    DOI: 10.1007/s00134-022-06745-7

  2. The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial.

    Wu J · 2025 · BMJ

    Study design
    Randomized controlled trial
    Research context
    Human research
    Sample size
    1106 participants or samples
    Study population
    Adults ages 18–85 with sepsis

    PMID: 39814420

    DOI: 10.1136/bmj-2024-082583

Bibliographic references do not establish the identity, purity, safety, effectiveness, or suitability of this catalog item and are not use guidance. For legitimate laboratory and research use only; not for human or veterinary use.

Related catalog